H. Lundbeck A/S Class A · OMXCOP:HLUN_A
H. Lundbeck A/S Class A — FY2008 Earnings Presentation
76 slides from H. Lundbeck A/S Class A's earnings presentation, Mar 4, 2009
Slide 1: Investor presentation - FY2008 financial results
H. LUNDBECK A/S Investor presentation - FY2008 financial results (4 March 2009)
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and inaccurate
Slide 3: Agenda
Agenda Lundbeck overview Products in development Marketed products Financial figures 3
Slide 4: Update on recent events
Update on recent events Strategic Lundbeck to acquire US based Ovation Pharmaceuticals, Inc. following FTC clearance “Decisions Now” process ongoing Financials Continued solid growth in all our products and regions Pipeline progression Patient recruitment on Lu AA21004 and Lu AA24530 accordi
Slide 5: “Decisions Now” – the workstreams or the 5Ps
“Decisions Now” – the 5 workstreams or the 5Ps Products – Achieving the full potential of marketed pharmaceuticals Pipeline – Maximising the value of new, innovative pharmaceuticals Performance – A high-growth, Increasing efficiency and reducing costs research based, CNS company Partners – Intensify
Slide 6: Aspiration to be a high-growth, research based, CNS company
It's Lundbeck’s aspiration to be a high-growth, research based, CNS company PLEASE NOTE: Ovation acquisition subject to approval by FTC Leverage on CNS capabilities to develop novel compounds to Successful product address unmet medical launches needs Implement strategy to - Lu AA21004 (mood Potentia
Slide 7: Lundbeck – a fully integrated company focusing on CNS
Lundbeck – a fully integrated company focusing on CNS PLEASE NOTE: Ovation acquisition subject to approval by FTC Lundbeck’s therapeutic areas (growth 2007 in%) USDm 25,000 ) %4 ) (1 4% Global is (- s CNS, largest therapeutic area, ho n pharmaceutical io yc ss Ps market 2007 17% of total pharmaceu
Slide 8: Lundbeck is involved in indications with high unmet medical needs
Lundbeck is involved in indications with high unmet medical needs PLEASE NOTE: Ovation acquisition subject to approval by FTC Rank* Disease Cipralex® / Lexapro® Launched 1 Cancer Lu AA21004 Clinical phase III 2 Unipolar depressive disorder and anxiety Lu AA24530 Clinical phase II Lu AA34893 Clinical
Slide 9: Agenda
Agenda Lundbeck overview Products in development Marketed products Financial figures 9
Slide 10: Depression and anxiety – efficacy and onset of action needs improvement
Depression and anxiety – efficacy and onset of action needs improvement Treatment for non-responders - only some The global market for anti-depressants 50-60% of patients respond to therapy constitutes USD 19.8bn Importance (higher for escitalopram) The market grew by 9% in Europe (2007) 150m
Slide 11: Portfolio within mood disorders
The portfolio within mood disorders – markedly different to any marketed antidepressants Portfolio of three innovative novel compounds Clinical programme on Lu AA21004: Clinical phase II concluded in Autumn 2007: Lu AA21004 6 weeks treatment Lu AA24530 429 patients Lu AA34530 Two doses: 5 an
Slide 12: Lu AA21004 – receptor profile
Lu AA21004 – receptor profil SSRI Lu AA21004 offers Pharmacological profile different from current 5HTT antidepressants Serotonin Increases multiple neuro-transmitters Occupancy rate: 80% 5-HT3 antagonist, 5-HT1A agonist and 5-HT enhancer Increases 5-HT levels at low 5-HT transporter occupan
Slide 13: Psychosis – still substantial unmet medical needs
Psychosis – still substantial unmet medical needs in therapy The global market for anti-psychotics Improved treatment of constitutes USD 21bn Importance cognitive dysfunction In 2007 the US market grew by 12% Improved treatment of The European market grew by 9% Negative symptoms 50-60% of to
Slide 14: The burden of schizophrenia is large and multifaceted
The burden of schizophrenia is large and multifaceted Brain disorders account for 35% of total socio-economic cost of diseases in Europe Schizophrenia is heavily stigmatized = Yearly cost (EURbn) Prevalence (mio.) create a vicious cycle of discrimination 120 45 40 Prevalence 100 Costs 35 Social
Slide 15: Lundbeck’s psychosis portfolio
Lundbeck’s psychosis portfolio Lundbeck’s portfolio addresses the Sertindole (US) patho-physiology with mono and add-on therapies Bifeprunox Lu AE58054 The different symptom domains may have a different patho-physiology Lu 31-130 One compound for all symptoms Lu AA39959 may not be realistic 0
Slide 16: Serdolect has market potential in the US
Serdolect® has market potential in the US NDA submitted in September Complete response letter expected in May 2009 Broadly efficacious against positive and negative symptoms The US anti-psychotics market is valued at USD 12.6bn per year Low rate of suicide Annual growth of around 12% I
Slide 17: The Sertindole Cohort Prospective (SCoP) study
The Sertindole Cohort Prospective (SCoP) study Designed in close collaboration with CHMP in 2002 Overall study design Prospective, randomised, naturalistic, open-label study Sertindole Primary objective: Randomise Follow-up Risperidone To compare the all-cause mortality of sertindole to that
Slide 18: Bifeprunox – additional clinical phase III trials initiated
Bifeprunox – additional clinical phase III trials initiated Bifeprunox is a partial dopamine D2 and 5-HT1A receptor agonist Bifeprunox target population IP 2017 + possible extensions Clinical trial design Severity of schizophrenia symptoms Two clinical phase III trials; each enrolling 450 Non-
Slide 19: Lu 31-130 – pharmacological profile and expected clinical profile
Lu 31-130 – pharmacological profile and expected clinical profile Lu 31-130 Two Phase II studies ongoing: Lu 31-130 has a multi-receptorial Clinical trial programme 1 profile A phase II, placebo controlled, dose- Affinity to monoaminergic escalation study in 210 patients with receptors schizophr
Slide 20: Lu AE58054 – pharmacological profile in animal models
Lu AE58054 – pharmacological profile in animal models Lu AE58054 has been investigated in healthy volunteers and patients with schizophrenia Is generally well tolerated and has a Lu AE58054 Lu AE58054 is a selective 5-HT6 benign side-effect profile antagonist Initiation and conduct of clinical
Slide 21: Bipolar disorder – still substantial unmet medical needs
Bipolar disorder (BPD) – still substantial unmet medical needs in therapy The prevalence is estimated around 1% Mono-therapies that treat depression Bipolar disorder (or manic-depressive illness is Importance and manic stage a chronic and debilitating psychiatric illness Improved maintenance the
Slide 22: Lu AA39959 – a new class of compounds targeting bipolar disorder
Lu AA39959 – a new class of compounds targeting bipolar disorder Lu AA39959 is expected to show clear and Lu AA39959 convincing effects in patients with bipolar disorder, Lu AA39959 has a unique target likely associated with profile: first in class Modulator of selected Benign safety/tolerabilit
Slide 23: Stroke – still substantial unmet medical needs
Stroke – still substantial unmet medical needs in therapy Unmet medical need: Thrombolytics with a longer Acute Ischemic stroke (AIS) accounts for 67-85% of all Importance treatment window strokes AIS is a leading cause of death in the major pharmaceutical markets and the leading cause of severe
Slide 24: Desmoteplase (ph III) – a possible improvement of existing stroke therapy
Desmoteplase (ph III) – a possible improvement of existing stroke therapy Responder rates DIAS/DEDAS DIAS-2 (pooled) Desmoteplase Nine hour time window increases 50% addressable market 40% Potential to decrease bleeding complications 30% Potential to improve neurological outcome 20% Post-hoc
Slide 25: Alcohol misuse – still substantial unmet medical needs
Alcohol misuse – still substantial unmet medical needs in therapy Unmet medical need: Greater resources - the number of treatment Alcohol exerts an influence on the glutamine, gamma- Importance facilities and trained physicians is inadequate aminobutyric acid (GABA) dopamine, and endogenous opioid
Slide 26: Nalmefene (ph III) – a potential new treatment paradigm
Nalmefene (ph III) – a potential new treatment paradigm Nalmefene Clinical phase III study ongoing: In clinical trials nalmefene reduces Consists of three studies with a total of Heavy Drinking Days ~1,800 patients Total consumption Two placebo-controlled 24-week Nalmefene can leverage o
Slide 27: Epilepsy – still substantial unmet medical needs
Epilepsy – still substantial unmet medical needs in therapy PLEASE NOTE: Ovation acquisition subject to approval by FTC Prevalence of epilepsy: 1% to 2% of population New and better treatment for 30% live with seizures uncontrolled by existing Importance refractory seizures therapies More choice
Slide 28: Sabril (vigabatrin) in refractory complex partial seizures
Sabril® (vigabatrin) in refractory complex partial seizures (rCPS) PLEASE NOTE: Ovation acquisition subject to approval by FTC Clinically meaningful improvements noted Complete seizure freedom (7-12%) Significant reductions in seizure frequency (> 50% Sabril® * and > 75% criteria) Unique MoA a
Slide 29: Sabril (vigabatrin) in infantile spasms
Sabril® (vigabatrin) in infantile spasms (IS) PLEASE NOTE: Ovation acquisition subject to approval by FTC Infantile spasms (IS) / West syndrome: Sabril® * Serious and catastrophic disease with unmet Unique MoA as a selective and irreversible medical need inhibitor of GABA-transaminase Seizures s
Slide 30: Clobazam and I.V. carbamazepine - overview
Clobazam and I.V. carbamazepine - overview PLEASE NOTE: Ovation acquisition subject to approval by FTC Clobazam Intravenous carbamazepine Clobazam is a 1,5-benzodiazepine Efficacy in Lennox-Gastaut Syndrome Niche product used in hospital (LGS) demonstrated in phase II channels for patients takin
Slide 31: ATryn (anti-thrombin [recombinant]) - overview
ATryn® (anti-thrombin [recombinant]) - overview PLEASE NOTE: Ovation acquisition subject to approval by FTC Hereditary Anti-thrombin Deficiency ® ATryn A potentially life-threatening rare disease Treatment of patients with with limited therapeutic alternatives Hereditary Anti-thrombin Deficiency
Slide 32: Lundbeck’s development pipeline
Lundbeck’s development pipeline Compound NDA Activity Phase I Phase II Phase III Indication Filing ATryn® Antithrombin alfa Approved Hereditary antithrombin deficiency Sabril® * GABA transaminase inhibitor Refractory complex partial seizures/ Infantile spasms Serdolect® - US Dopamine/serotonin Schiz
Slide 33: Agenda
Agenda Lundbeck overview Products in development Marketed products Financial figures 33
Slide 34: Cipralex/Lexapro (escitalopram) - top of the class anti-depressant
Cipralex®/Lexapro® (escitalopram) - top of the class anti-depressiv Cipralex® is an ANRI* with a unique mode of action, Serotonin Dual-action Estimated to have treated more than 160 million patients since launch Has demonstrated superior efficacy in the treatment of depression and anxiety in n
Slide 35: Cipralex - Still gaining market shares in most markets
Cipralex® (escitalopram) - Still gaining market shares in most markets Anti-depressant marked Market growth, Market share, Cipralex® sales in Europe for the year was DKK 3,355m volume Europe value 12% 16.8% 18% (+19%) 16% 10% Cipralex® still the most subscribed branded anti- 14% depressant in Eu
Slide 36: Lexapro - still most prescribed brand in the US
Lexapro® (escitalopram) - still most prescribed brand in the US Anti-depressant market US US sales of DKK 2,464m in 2008, down 3% Market growth, Market share, volume value compared to 2007 9% 22.9% 25% Reduction of Lexapro® inventories in the US 7% 20% reduced Lundbeck revenue by DKK 256m in 5%
Slide 37: Ebixa (memantine) – efficacious even in severe Alzheimer’s disease
Ebixa® (memantine) – efficacious even in severe Alzheimer’s disease Ebixa® is the only NMDA* receptor antagonist approved for the treatment of Alzheimer’s disease A very efficacious, well-tolerated and safe treatment with placebo-like side effects Only therapy licensed for the treatment of mod
Slide 38: Ebixa – growth driven by underlying market development
Ebixa® (memantine) – growth driven by underlying market development Anti-Alzheimer’s market Market growth, Market share, Ebixa® sales grew 14% compared to 2007 to volume Europe value DKK 1,879m. 20% 16.0% 18% 16% 15% European sales at DKK 1,557m (+15%) 12% 12% European market share is stable a
Slide 39: Azilect (rasagiline) – only treatment proven to slow Parkinson’s progression
Azilect® (rasagiline) – only treatment of Parkinson’s disease proven to slow disease progression A potent, selective, irreversible monoamine oxidase (MAO) type-B inhibitor Approved for monotherapy and adjunct therapy with levodopa treatment Azilect® is a well tolerated therapy for early and ad
Slide 40: Azilect – strong growth across all markets
Azilect® (rasagiline) – strong growth across all markets Anti-Parkinson’s market Market growth, Europe Market share, Azilect® sales rose to DKK 263m in 2008, up volume 6% value 6.5% 7% 57% compared to 2007 5% 6% European sales at DKK 241m (+54%), Int. 4% 5% Markets sales at DKK 22m (+84%) 4% 3%
Slide 41: Xenazine – promising initial launch
Xenazine* (tetrabenzine) – promising initial launch PLEASE NOTE: Ovation acquisition subject to approval by FTC Highly selective and reversible dopamine depletor Approved for chorea associated with Huntington’s disease - launched in November 2008 Only drug approved by FDA specifically for any
Slide 42: Agenda
Agenda Lundbeck overview Products in development Marketed products Financial figures 42
Slide 43: Financial figures – distribution of revenue in 2008
Financial figures – distribution of revenue in 2008 DKKm DKKm 13% 2006 2007 2008 Lundbeck’s revenue excluding one-offs grew 7,000 (14%) 7% Growth DKK 7% in 2008 to DKK 11,282m which is the (8%) 6,000 Growth LC highest ever 5,000 4,000 Revenue growth driven by Europe and 35% -5% 3,000 6,213 (39%)
Slide 44: Financial figures – distribution of costs in 2008
Financial figures – distribution of costs in 2008 DKKm 10,000 COGS SG&A R&D 7,909 8,449 R&D costs excl. one-offs for 2008 is 8,000 7,437 7,179 6,900 22% up 15% compared to 2007, 21% 6,000 19% 20% 22% corresponding to 22% of total revenue 4,000 37% 36% 39% 42% 40% R&D costs to increase in 2009 2,
Slide 45: Key deliverables the next 12 months
Key deliverables the next 12 months PLEASE NOTE: Ovation acquisition subject to approval by FTC Corporate Approval of the Ovation acquisition Existing products Life-cycle management initiatives for escitalopram FDA decision on Serdolect® in the US for schizophrenia (preliminary hearing 7 April
Slide 46: Financial guidance
Financial guidance PLEASE NOTE: Financial guidance is excluding Ovation Pharmaceuticals Positives 2008 Organic sales growth of 6- 2009* 11% expected for 2009 Excl. one-offs (DKKbn) (DKKm) Continued solid performance for most of our major products Revenues 11,282 12-12.5 Currency development
Slide 47: Multiple strategies to drive long-term growth
Multiple strategies to drive long-term growth Our path forward… Streamline current business Explore opportunities on Lundbeck’s strengths commercial products • A specialist in Market potential psychiatry and pioneer Delivering on our late-stage in neurology • Large market portfolio, but… oppor
Slide 48: For more information please contact Investor Relations
For more information please contact Investor Relations Jacob Tolstrup Palle Holm Olesen Joan Loua Director; IR and Communication Head of Investor Relations Investor Relations coordinator Tel: +45 36 43 30 79 Tel: +45 36 43 24 26 Tel: +45 36 43 45 98 Fax: +45 36 43 82 62 Fax: +45 36 43 82 62 Fax: +45
Slide 49: Appendix
Appendix 49
Slide 50: Lundbeck share
Lundbeck share Share information: Trading code: Free float (approximately 60m Reuters (LUN.CO) / Bloomberg (LUN DC) shares) is traded 1.5+ time over ISIN Number DK0010287234 annually (daily trade of approximately Unsponsored ADR programmes 0.35m) HLUKY, CUSIP 40422M107 Index examples: End
Slide 51: Continued solid performance in all products
Continued solid performance in all products Cipralex® • Results from a a multiple-treatments meta-analysis comparing efficacy and acceptability of 2 new-generation Market share Y/Y antidepressants support Cipralex1) (Dec 2008) Change • “Decisions Now” Cipralex® • Venlafaxine patent expiration - Euro
Slide 52: Revenue – by product / by region (yearly)
Revenue – by product / by region (yearly) International Total Europe USA Markets DKKm 2008 2007 2008 2007 2008 2007 2008 2007 Total revenue 11,282 10,985 6,213 5,501 2,464 2,599 2,409 2,194 Growth 3% 13% -5% 10% Cipralex® 4,829 4,094 3,355 2,827 - - 1,474 1,267 Growth 18% 19% 16% Lexapro® 2,464 2,59
Slide 53: Revenue – by product / by region (quarterly)
Revenue – by product / by region (quarterly) International Total Europe USA Markets Q4 Q4 Q4 Q4 Q4 Q4 Q4 Q4 DKKm 2008 2007 2008 2007 2008 2007 2008 2007 Total revenue 2,653 2,830 1,564 1,396 509 626 530 523 Growth -6% 12% -19% 1% Cipralex® 1,151 1,031 830 720 - - 321 311 Growth 12% 15% 3% Lexapro® 5
Slide 54: Revenue – by product / by region
Revenue – by product / by region Revenue, DKK million Growth, Y/Y, % 2004 2005 2006 2007 2008 2005 2006 2007 2008 Total revenue 9,733 9,070 9,221 10,985 11,282 -7% 2% 19% 3% Cipralex® 1,661 2,625 3,508 4,094 4,829 58% 34% 17% 18% Lexapro® 2,420 2,552 1,923 2,594 2,464 5% -25% 35% -5% Ebixa® 722 1,10
Slide 55: Revenue, quarterly figures
Revenue, quarterly figures Revenue, DKK million Growth, Y/Y, % Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2008 2008 2008 2008 2008 2008 2008 Total revenue 2,882 2,938 2,810 2,653 12% 12% -5% -6% Cipralex® 1,216 1,234 1,228 1,151 23% 20% 17% 12% Lexapro® 661 692 602 509 5% 8% -14% -19% Ebixa® 457 467 480 475 17% 1
Slide 56: Costs, year figures
Costs, 5 year figures DKK million Growth, Y/Y, % 2004 2005 2006 2007 2008 2005 2006 2007 2008 Revenue 9,733 9,070 9,221 10,985 11,282 -7% 2% 19% 3% Production costs 1,725 1,488 1,646 2,198 1,837 -14% 11% 34% -16% Distribution costs 2,302 2,337 2,419 2,409 2,459 2% 4% 0% 2% Administrative exp. 1,364
Slide 57: Costs, quarterly figures
Costs, quarterly figures DKK million Growth, Y/Y, % Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2008 2008 2008 2008 2008 2008 2008 Revenue 2,882 2,938 2,810 2,653 12% 12% -5% -6% Production costs 476 469 432 460 -4% 18% -5% -46% Distribution costs 567 632 571 689 -2% 7% -2% 4% Administrative expenses 399 427 386 4
Slide 58: USD hedging on a rolling basis – 2009 hedge rate
Lundbeck hedge the USD on a rolling basis around 12 months ahead – 2009 USD hedge rate of 5.32 Actual rates Forward rates 10 9 8 7 6.68 6.00 6 5.83 5.51 5.89 5.31 5.75 4.96 4.99 5 Quarterly figures 4 '04 '05 '06 '07 '08 Q1 Q2 Q3 Q4 '09 '09 '09 '09 Average US$ exchange rate Average hedging US$ rate N
Slide 59: Ovation overview
Ovation overview PLEASE NOTE: Financial guidance is excluding Ovation Pharmaceuticals Company was founded by Jeffrey Aronin and started commercial operations in 2002 Headquartered in Deerfield, IL Approximately 300 employees Professional interaction with Key Opinion Leaders, patient organisa
Slide 60: Solid historic performance in Ovation
Solid historic performance in Ovation – Brain disorders to be key future revenue driver PLEASE NOTE: Ovation acquisition subject to approval by FTC Revenue distribution (2008e) Ovation - historic performance USDm 2005 2006 2007 2008e 27% Net sales 60.1 142.7 176.1 204.0 Growth % 55% 137% 23% 16% Gro
Slide 61: Ovation transaction – financial highlights
Ovation transaction – financial highlights PLEASE NOTE: Ovation acquisition subject to approval by FTC Financing uses Lundbeck revenue, geographic breakdown Transaction value USDm (2008e) initial payment 600 US contingent payment up to 300 22% US Total transaction value up to 900 29% Financi
Slide 62: Insomnia is still a market with unmet medical needs
Insomnia is still a market with unmet medical needs Disorders co-morbid with insomnia Insomnia: (Patients visiting physician with sleep problems and co-morbid condition) 70 million adults suffer from insomnia – 25 million with chronic and/or severe 100% insomnia 90% The prevalence of insomnia in
Slide 63: Circadin (melatonin) - A novel treatment form for insomnia
Circadin® (melatonin) - A novel treatment form for insomnia Melatonin is a naturally occurring hormone and is important in the regulation of the circadian rhythms Mimics the natural melatonin profile by releasing melatonin gradually over 8-10 hours Indicated as monotherapy for the short-term t
Slide 64: Roll-out of Circadin initiated in May in Europe
Roll-out of Circadin® initiated in May in Europe – initial feedback is positive Circadin® in Europe: Lundbeck has rights for approx. 80% of the European market (approx. USD 800m) Indicated as monotherapy for the short-term treatment of primary insomnia in patients aged 55+ Fits well into Lundb
Slide 65: Bifeprunox is expected to improve schizophrenia symptoms long-term
Bifeprunox is expected to improve schizophrenia symptoms over the long-term Symptoms were stable over 6 months on bifeprunox In clinical trials bifeprunox has shown: treatment in a time-to-deterioration trial Anti-psychotic effect (acute+chronic) In chronic, stabilised schizophrenia, bifeprunox
Slide 66: Global IP position
Global IP position Europe Bifeprunox: Compound patent in majority of countries to Feb. 2017 (excl. extension) Escitalopram: Compound patent in majority of countries to May-June 2014. Process patent in majority of countries to June 2014 Memantine: Data exclusivity until 2012; use patent until 2014 (i
Slide 67: Worldwide pharmaceutical market 2007
Worldwide pharmaceutical market 2007 – USD 671.7 billion (+10%) 8% (+13%) 17% (+10%) 3% (+11%) 5% (+10%) (N) CNS (C) Cardiovascular 5% (+11%) (A) Alimentary (J) Anti-Infectives 15% (+2%) 6% (+5%) (L) A+Immun (R) Respiratory (B) Blood 8% (+13%) (M) Muscolo-Skeletal (G) G.U.& Sex Hormones (D) Dermatol
Slide 68: Worldwide CNS market 2007
Worldwide CNS market 2007 – USD 111.8 billion (+10%) 11% (+22%) 19% (+14%) 2% (+6%) N5A Antipsychotics 2% (+3%) N6A Antidepressants 3% (+8%) N3A Anti-Epileptics N2B Non-Narcotic Analgesics 3% (+19%) N2A Narcotic Analgesics 4% (-8%) N7D Anti-Alzheimers 18% (-4%) N5B Hypnotics & Sedatives 5% (+21%) N4
Slide 69: Alcohol (N7E-2007)
Alcohol (N7E-2007) – USD 172 million (+22%) International markets 11% (14%) North America 36% (+46%) Europe 53% (+12%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Campral® Merck 74 11 Antabuse® Barr/Sanofi-Aventis 26 48 Nemexin® BMS/Cephalon 11 7 Vivitrol® BMS/Cephalon 11 479
Slide 70: Anti-Alzheimer’s (N7D-2007)
Anti-Alzheimer’s (N7D-2007) – USD 5.6 billion (+21%) International markets Value Market Shares of N7D 16% (+29%) Europe M12 2007 USA M12 2007 Rivastigmine Memantine Europe 30% (+22%) North Galantamine America 54% (+19%) Donepezil 0% 10% 20% 30% 40% 50% 60% Source: IMS Health, May 2008, retail only L
Slide 71: Anti-depressants (N6A-2007)
Anti-depressants (N6A-2007) – USD 19.8 billion (- 4%) International Value Market shares of N6A markets 13% (+15%) VENLAFAXINE SERTRALINE PAROXETINE FLUOXETINE Europe M12 2007 North America USA M12 2007 Europe 62% (-12%) ESCITALOPRAM 25% (+9%) DULOXETINE CITALOPRAM BUPROPION 0% 5% 10% 15% 20% 25% 30%
Slide 72: Anti-epileptics (N3A - 2007)
Anti-epileptics (N3A - 2007) – USD 15.3 billion (+17%) PLEASE NOTE: Ovation acquisition subject to approval by FTC International markets 11% (+18%) Europe North America 22% (+21%) 67% (+15%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Topamax® J&J 2496 17 Lamictal® GlaxoSmith
Slide 73: Anti-Parkinson’s (N4A - 2007)
Anti-Parkinson’s (N4A - 2007) – USD 3.7 billion (+19%) Value Market Shares of N4A - Europe International North Europe M12 2007 markets America Stalevo® 21% (+8%) 36% (+23%) NMDA ANTAGONISTS MAOI LEVODOPA DERIVATE DOPAMINE AGONISTS COMT INHIBITORS ANTICHOLINERGICS 0.00% 10.00% 20.00% 30.00% 40.00% 50
Slide 74: Anti-psychotics (N5A-2007)
Anti-psychotics (N5A-2007) – USD 20.8 billion (+14%) International Value Market Shares of N5A Europe M12 2007 markets ZIPRASIDONE USA M12 2007 11% (+17%) RISPERIDONE QUETIAPINE OLANZAPINE North America CLOZAPINE Europe 64% (+12%) 26% (+19%) ARIPIPRAZOLE AMISULPRIDE 0% 5% 10% 15% 20% 25% 30% 35% Sour
Slide 75: Hypnotics (N5B-2007)
Hypnotics (N5B-2007) – USD 5.0 billion (- 8%) Value Market Shares of N5B International Europe Q4 2007 markets Ezopiclone USA Q4 2007 17% (+4%) Zaleplon Zopiclone Europe North 22% (+10%) America Zolpidem 61% (-16%) 0% 10% 20% 30% 40% 50% 60% 70% 80% Source: IMS Health, May 2008, retail Leading produc
Slide 76: Stroke, Fibrinolytics (B1D-2007)
Stroke, Fibrinolytics (B1D-2007) – USD 743 million (+10%) International markets 19% (+14%) North America 49% (+6%) Europe 32% (+13%) Leading product Marketing Corporation Sales 2007 (USDm) Growth in % Activase®/Actilyse® Roche/Boehringer 365 20 Metalyse®/Tnkase Roche/Boehringer 166 (1) Retavase®/Rap